BRCA1 and BRCA2 genes play a crucial role in repairing damaged DNA. Mutations in BRCA1 and BRCA2 substantially increase the likelihood of breast and ovarian cancer, respectively. This new research ...

These cancers are, however, quite sensitive to anticancer drugs such as poly (ADP-ribose) polymerase inhibitors (PARPi). When successful, these cancer treatments cause enough DNA damage to trigger ...

Research by UMass Chan Medical School scientists Sharon Cantor, Ph.D., and Jenna M. Whalen, Ph.D., poses a new explanation for how cancer-fighting drugs attack and destroy BRCA1 and BRCA2 tumor cells.

IMNN READ THE FULL IMNN RESEARCH REPORT Business Update Phase 3 Ovarian Cancer Trial to Initiate in March 2025 Imunon, Inc. (NASDAQ:IMNN) is continuing preparations to conduct a Phase 3 clinical trial ...

PDOs predict treatment responses, facilitate drug testing, and uncover drug resistance mechanisms ... is a stable biomarker in ovarian cancer (OC). PARP inhibitors (PARPi) exploit HRD via synthetic ...

PARPi, poly ADP-ribose polymerase inhibitor; FAERS, Food and Drug Administration Adverse Event Reporting System; MDT, multidisciplinary team.

OCOG-RATIONAL: A phase II randomized trial of optimal recurrence-directed therapy (RDT) without or with androgen-deprivation therapy (ADT) in radio-recurrent oligo-metastatic castrate sensitive ...